Results of Intravitreal Anti-VEGF Injection in Choroidal Neovascularizations Caused by Pathologies Other Than Age-Related Macular Degeneration

Abstract

The aim of this retrospective study was to evaluate the efficacy of the intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents to treat choroidal neovascularization (CNV) caused by a pathology other than exudative type age-related macular degeneration (AMD). Methods: This was a retrospective study of 43 treatment naive eyes of 35 patients who had been diagnosed with CNV caused by a pathology other than exudative-type AMD and who underwent intravitreal injection of anti-VEGF agents. Primary and secondary outcome measures were the best corrected visual acuity (BCVA) and the central macular thickness (CMT). Results: The mean patient age was 44.6±13.1 years. The mean number of injections was 3.3±1.8. The mean logarithm of minimal angle of resolution BCVA at baseline and the 12 th month follow-up was 0.89±0.50 and 0.73±0.57, respectively (p=0.120). In all, 44.2% of the eyes gained ≥15 letters of BCVA, whereas 14% lost ≥15 letters of BCVA. The mean CMT at baseline and the 12 th month follow-up was 381±121 and 311±73 microns, respectively (p=0.001). Conclusion: Stabilized functional and improved anatomic outcomes following intravitreal anti-VEGF agent injection for CNV unrelated to AMD were seen at the 12 th month of follow-up.

Oxidative Stress and Antioxidants in Age-Related Macular Degeneration

“…The current best available treatment for wet AMD is intravitreal injections of anti-VEGF therapies of aflibercept and ranibizumab [99]. Overall, these anti-VEGF agents are well accepted and effective in treating neovascular AMD, with reduction in CNV formation and improved visual ability [100]. However, limitations exist, including the need for frequent injections and treatment cost.…”